newsfilter
← Latest News
GlobeNewswire·

Kymera Therapeutics Announces Gilead Sciences' Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate

KT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate Option exercise of KT-200 triggers a $45 million milestone payment to Kymera from Gilead Sciences WATERTOWN, Mass., April 09, 2026